Slide 1: Target population/question

Slides:



Advertisements
Similar presentations
1. Describe the pathogenesis of hyperuricemia and gout Goup C1 Group C1.
Advertisements

JNC 8 Guidelines….
Wrap-Up and Post Course Self Assessment Dr. Diane Lacaille.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Purine Degradation & Gout (Musculoskeletal Block)
Gout.
Gout : Clinical review and trial design issues Joel Schiffenbauer FDA/DAAODP AAC/June 3, 2004.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Uric Acid Metabolism & Gout
Diagnosis of gout.
More than 100 different disorders
Definition of Gout Definition of Gout Pathological classification Pathological classification History of Gout History of Gout Gout Aetiology & Pathogenesis.
Diagnosis & Treatment of Gout
Screening Introduction to Primary Care:
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
GOUT: DIAGNOSIS AND MANAGEMENT. Gout Metabolic disorder due to excessive accumulation of uric acid in tissues leading to acute and chronic arthritis and.
Gout. The most common cause of inflammatory arthritis in US adults (3.9% of Americans; approx. 8.3 million people; ) Prevalence is greater in.
StagesClinical Features (1)Asymptomatic hyperuricemiahigh uric acid level is present but without symptoms (2) Acute Gouty Arthritishigh uric acid level.
Anna Pardue NS Methodist University.  As we known “Rich man’s disease.”  Inflammatory arthritis, a metabolic disorder that causes the deposition of.
Backgrond  Ankylosing spondylitis Condition in the spondyloarthritis (SpA) family of disease Chronic inflammatory arthritis characterized by sacroiliitis,
GERIATRICS Dr. Meg-angela Christi Amores. Musculoskeletal Disorders in the Elderly  Osteoarthritis  Rheumatoid Arthritis  Gout (Gouty arthritis) 
© Copyright Annals of Internal Medicine, 2016 Ann Int Med. 165 (1): ITC1-1. In the Clinic Gout.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and.
Acute Kidney Injury. 100,000 deaths are year are associated with acute kidney injury. (NCEPOD 2009)
Purine Degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
Screening System for Hypertension and Diabetes at Primary Care Level
Gout Ashley Guzman Primary Care I: Acute and Chronic Health Problems
T.Vasilopoulos1, C.Tatsi1, C. Lionis1
GOUT GOUT.
Crystalopathies Joanna Zalewska.
Gout Asad Khan Consultant Rheumatologist
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Image Reading Course in Nuclear Medicine
Redefining Quality Care in T2DM Patients with CV Disease
History Salient Features Physical Exam
Drug Therapy of Gout 1.
Mr. Smith, 51, came to the family doctor because of severe pain in his left knee. The patient gave the pain began suddenly at 2 am, woke him from his.
EULAR June 2018 EULAR points to consider for reporting/screening and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily.
Target population/question
Prevention Cardiovascular disease
FINAL Recommendations
EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures Ann Rheum Dis.
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders:
Slide 1: Target population/question
EULAR Recommendation/Points to Consider Slide set template Slide set should, if possible, not exceed 20 Slides Please submit slide set along with final.
Wrap-Up and Post Course Self Assessment
Diffuse Idiopathic Skeletal Hyperostosis (DISH) Study Group
Figure 1 Proposed algorithm for the management
EULAR Study Group on patient education
How to Find Relief & Reduce Flare-Ups
Gout Scott Smith PGY-1 1/11/2018.
Tips for Written assignment HSNS265
Table of Contents Why Do We Treat Hypertension? Recommendation 5
TREATMENT OF THE ACUTE GOUT ATTACK:
Purine Degradation & Gout (Musculoskeletal Block)
What on earth is Spondyloarthritis
Purine Degradation & Gout (Musculoskeletal Block)
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Synovial Biopsy in Patients with UPIA
The Study Group aims to:
Target population/question
European League Against Rheumatism points to consider for the use of big data in rheumatic and musculoskeletal diseases.
2019 Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD)
Slide 1: Target population/question
EULAR Points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with.
Dual-energy CT images. Dual-energy CT images. Arrows indicate MSU deposition (MSU deposits colour coded in green). (A) Subject accuracy study with acute.
EULAR Recommendation/Points to Consider Slide set template Slide set should, if possible, not exceed 20 Slides Please submit slide set along with final.
Presentation transcript:

2018 Updated EULAR Evidence-based Recommendations for the Diagnosis of Gout

Slide 1: Target population/question In 2006, the EULAR produced its first evidence-based recommendations for the diagnosis of gout. Since then, a number of studies have explored the diagnostic value of clinical algorithms and of imaging modalities such as ultrasound (US) or dual-energy computed tomography (DECT). This prompted a revision of the 2006 recommendations following an updated systematic literature review (SLR) and a Delphi process to achieve consensus Target population: Rheumatologists, GPs, and all Health care providers who manage people with Gout 23/11/2019

Slide 2: Methods/methodological approach Methods: According to the EULAR Standardized Operating Procedures* Consensual approach Systematic literature research FINAL Recommendations * van der Heijde et al Ann Rheum Dis 2016,75:3-15 23/11/2019

Slides 3-4: Overarching principles Since we formulated only 8 recommendations, we did not propose overarching principles 23/11/2019

Slides 5-15: Individual Recommendations Search for crystals in synovial fluid or tophus aspirates is recommended in every person with suspected gout, because demonstration of MSU crystals allows a definitive diagnosis of gout (LoA=8.6). 2 Gout should be considered in the diagnosis of any acute arthritis in an adult. When synovial fluid analysis is not feasible, a clinical diagnosis of gout is supported by the following suggestive features: mono articular involvement of a foot (especially the first MTP) or ankle joint; previous similar acute arthritis episodes; rapid onset of severe pain and swelling (at its worst in <24 h); erythema; male gender; and associated cardiovascular diseases and hyperuricemia. These features are highly suggestive but not specific for gout (LoA=8.6). 3 It is strongly recommended that synovial fluid aspiration and examination for crystals is undertaken in any patient with undiagnosed inflammatory arthritis (LoA=8.8). 4 The diagnosis of gout should not be made on the presence of hyperuricemia alone (LoA=8.9). 5 When a clinical diagnosis of gout is uncertain and crystal identification is not possible, patients should be investigated by imaging to search for urate deposits and features of any alternative diagnosis (LoA=8.5). 6 Plain radiographs are indicated to search for features of chronic urate arthropathy but have limited value for the diagnosis of acute gouty arthritis. Ultrasound scanning can be more helpful in establishing a diagnosis in patients with suspected acute or chronic gouty arthritis by detection of tophi not evident on clinical examination, or a double contour sign at cartilage surfaces, which is highly specific for urate deposits in joints (LoA=8.2). 7 Risk factors for chronic hyperuricemia should be searched for in every person with gout, specifically: chronic kidney disease; overweight, medications (including diuretics, low dose aspirin, cyclosporine, tacrolimus); consumption of excess alcohol (particularly beer and spirits), non-diet sodas, meat and shellfish (LoA=8.2). 8 Systematic assessment for the presence of associated co-morbidities in people with gout is recommended; including obesity, renal impairment, hypertension, ischemic heart disease, heart failure, diabetes and dyslipidemia (LoA=8.7). 23/11/2019

Slide 16: Summary Table Oxford Level of Evidence Recommendation Level of evidence Grade of recommendation Level of agreement (mean±SD) 1 2b B 8.6 +/- 1.0 2 8.6 +/- 0.8 3 C 8.8 +/- 0.3 4 2a 8.9 +/- 0.2 5 1b A 8.5 +/- 1.0 6 8.2 +/- 0.9 7 1a 8.2 +/- 1.3 8 8.7 +/- 0.6 23/11/2019

Slides 17-18: Summary of Recommendations in bullet point format The task force recommends a three step approach for the diagnosis of gout The first step relies on MSU crystal identification when SF analysis is feasible. If not possible, the second step relies on a clinical diagnosis based on suggestive and associated clinical features of gout and presence of hyperuricemia. When a clinical diagnosis of gout is uncertain and crystal identification is not possible, the third step recommends imaging, particularly ultrasound, to search for crystal deposits. [Secretariat will add link of recommendation once available online on BMJ portal.] 23/11/2019

Slides 19-20: Summary of Recommendations in lay format * In contact with EULAR Secretariat Betka Göhmann. Slide will be added at later stage Read the full lay summary (add hyperlink if provided) 1 star (*) means it is a weak recommendation with limited scientific evidence; 2 stars (**) means it is a weak recommendation with some scientific evidence; 3 stars (***) means it is a strong recommendation with quite a lot of scientific evidence; 4 stars (****) means it is a strong recommendation supported with a lot of scientific evidence. Recommendations with just 1 or 2 stars are based mainly on expert opinion and not backed up by appropriate clinical studies, but may be as important as those with 3 and 4 stars. 23/11/2019

Slide 21: Acknowledgements This paper is dedicated to the memory of Dr Victoria Barskova. The task force thanks EULAR for financial and logistic support. 23/11/2019